Reading view
The New Age of Cell-Free DNA in Pulmonary Medicine
Chest. 2025 Sep;168(3):581-583. doi: 10.1016/j.chest.2025.04.023.
NO ABSTRACT
PMID:40935546 | DOI:10.1016/j.chest.2025.04.023
Why the Oracle-OpenAI deal caught Wall Street by surprise
Fluctuating DNA methylation tracks cancer evolution at clinical scale
Nature, Published online: 10 September 2025; doi:10.1038/s41586-025-09374-4
Cancer evolutionary dynamics are quantitatively inferred using a method, EVOFLUx, applied to fluctuating DNA methylation.AI chatbots are already biasing research — we must establish guidelines for their use now
Nature, Published online: 09 September 2025; doi:10.1038/d41586-025-02810-5
The academic community has looked at how artificial-intelligence tools help researchers to write papers, but not how they distort the literature scientists choose to cite.Single-cell multiome and spatial profiling reveals pancreas cell type-specific gene regulatory programs of type 1 diabetes progression
Sci Adv. 2025 Sep 12;11(37):eady0080. doi: 10.1126/sciadv.ady0080. Epub 2025 Sep 10.
ABSTRACT
Cell type-specific regulatory programs that drive type 1 diabetes (T1D) in the pancreas are poorly understood. Here, we performed single-nucleus multiomics and spatial transcriptomics in up to 32 nondiabetic (ND), autoantibody-positive (AAB+), and T1D pancreas donors. Genomic profiles from 853,005 cells mapped to 12 pancreatic cell types, including multiple exocrine subtypes. β, Acinar, and other cell types, and related cellular niches, had altered abundance and gene activity in T1D progression, including distinct pathways altered in AAB+ compared to T1D. We identified epigenomic drivers of gene activity in T1D and AAB+ which, combined with genetic association, revealed causal pathways of T1D risk including antigen presentation in β cells. Last, single-cell and spatial profiles together revealed widespread changes in cell-cell signaling in T1D including signals affecting β cell regulation. Overall, these results revealed drivers of T1D in the pancreas, which form the basis for therapeutic targets for disease prevention.
PMID:40929272 | PMC:PMC12422192 | DOI:10.1126/sciadv.ady0080
Organoids in Genetic Disorders: from Disease Modeling to Translational Applications
Stem Cell Rev Rep. 2025 Sep 11. doi: 10.1007/s12015-025-10973-x. Online ahead of print.
ABSTRACT
The emergence of organoid models has significantly bridged the gap between traditional cell cultures/animal models and authentic human disease states, particularly for genetic disorders, where their inherent genetic fidelity enables more biologically relevant research directions and enhances translational validity. This review systematically analyzes established organoid models of genetic diseases across organs (e.g., brain, eye, kidney, lung, and heart), highlighting their pivotal roles in identifying novel pathogenic genes, elucidating disease mechanisms, and advancing therapeutic strategies such as drug screening platforms, gene-editing therapies, and organ transplantation strategies. Furthermore, we critically address current limitations-including challenges in recapitulating complex pathologies and scaling production-while underscoring their potential for personalized medicine through multi-omics integration and bioengineering innovations. Although the scope of "genetic diseases" is broad, this synthesis focuses on disorders with well-defined inheritance patterns, such as monogenic disorders, copy number variations (CNVs), and aneuploidies. Despite covering only a subset of these conditions, this review aims to provide researchers with a comprehensive overview of the field, emphasizing how organoid-based approaches could accelerate both mechanistic discoveries and clinical translation in genetic disease research.
PMID:40931310 | DOI:10.1007/s12015-025-10973-x
Liquid biopsy- A pivotal test to help navigate clinical decisions at a precision center in India!
J Liq Biopsy. 2025 Aug 9;9:100323. doi: 10.1016/j.jlb.2025.100323. eCollection 2025 Sep.
ABSTRACT
Liquid biopsy, specifically circulating tumor DNA (ctDNA) analysis, has emerged as a transformative tool in precision oncology, providing real-time, minimally invasive characterizations of the tumor and tumor dynamics. While tissue biopsy is a critical tool for baseline diagnosis of malignancy, it is often limited by sampling constraints and an inability to capture tumor heterogeneity. In this study, we explored the clinical utility of serial ctDNA testing in guiding therapeutic decisions across a cohort of 30 patients with diverse solid tumors. Our real-world analysis demonstrates that ctDNA profiling meaningfully influenced treatment escalation, de-escalation, disease monitoring, and early relapse prediction. Cases where ctDNA positivity indicated minimal residual disease prompted timely escalation of therapy, while ctDNA clearance allowed safe treatment de-intensification, minimizing toxicity without compromising outcomes. Longitudinal ctDNA monitoring provided a dynamic, non-invasive method for assessing treatment response and detecting recurrence months before radiological progression. Our study highlights the potential of integrating liquid biopsy into routine clinical practice to enable dynamic treatment monitoring, early detection of therapeutic resistance, and more informed, personalized decision-making across various cancer types.
PMID:40919127 | PMC:PMC12409318 | DOI:10.1016/j.jlb.2025.100323
Applications of Federated Large Language Model for Adverse Drug Reactions Prediction: Scoping Review
The WHO global landscape of cancer clinical trials
Nature Medicine, Published online: 09 September 2025; doi:10.1038/s41591-025-03926-x
This Review of the WHO’s International Clinical Trials Registry Platform presents a snapshot of the global cancer trial landscape and provides critical empirical evidence to inform policy, practice and investment.Building the world’s first truly global medical foundation model
Nature Medicine, Published online: 08 September 2025; doi:10.1038/s41591-025-03859-5
Building the world’s first truly global medical foundation modelOpinion: Bringing AI to medicine requires philosophers, cognitive scientists, and ethicists
“My watch saved my life.”
Liam — not his real name — is a 75-year-old retired teacher in Boston. Two years ago, his son-in-law gave him an Apple Watch. Soon after, it began flagging something strange: possible atrial fibrillation.


© Adobe
Antibody–bottlebrush prodrug conjugates for targeted cancer therapy
Nature Biotechnology, Published online: 09 September 2025; doi:10.1038/s41587-025-02772-z
Antibody–bottlebrush conjugates expand the options for drug cargos compared to antibody–drug conjugates.GASPS: A Multi-Omics Framework for Defining Genomic Aberration-Driven Signatures and Predicting Patient Outcomes in Lung Cancer
bioRxiv [Preprint]. 2025 Aug 25:2025.08.21.671519. doi: 10.1101/2025.08.21.671519.
ABSTRACT
Lung cancer is the most common cause of cancer-related death worldwide. Recent advancements in targeted therapies and immunotherapies have achieved remarkable success. However, patient responses to treatments with lung cancer vary substantially. The mutation status of driver genes can direct personalized treatment, but their prognostic value and treatment efficacy are limited. In this study, we developed a statistical framework named Genomic Aberration-Derived Signature for Patient Stratification (GASPS) to characterize the transcriptomic deregulation of driver genomic aberrations and stratify patients. By applying GASPS to The Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) data, we developed gene signatures for 38 driver genomic aberrations, including gene mutations, amplifications, and deletions. These signatures were applied to independent lung cancer transcriptomic datasets containing a total of 2,226 patient samples. Our results indicated that these driver gene signatures are much more prognostic than their corresponding genomic mutations. Interestingly, the two EGFR-related signatures characterizing EGFR mutation and amplification, respectively, exhibited contrasting associations with prognosis, treatment response, and immune infiltration in the tumor microenvironment. Moreover, the STK11 mutation signature, rather than the mutation status, was found to be predictive of the response and long-term benefit of patients treated with immune checkpoint blockade therapy in lung cancer. This framework is readily applicable to most cancer types using existing data to improve prognostic risk assessment and treatment efficacy by guiding personalized therapies.
PMID:40909579 | PMC:PMC12407784 | DOI:10.1101/2025.08.21.671519
GASPS: A Multi-Omics Framework for Defining Genomic Aberration-Driven Signatures and Predicting Patient Outcomes in Lung Cancer
bioRxiv [Preprint]. 2025 Aug 25:2025.08.21.671519. doi: 10.1101/2025.08.21.671519.
ABSTRACT
Lung cancer is the most common cause of cancer-related death worldwide. Recent advancements in targeted therapies and immunotherapies have achieved remarkable success. However, patient responses to treatments with lung cancer vary substantially. The mutation status of driver genes can direct personalized treatment, but their prognostic value and treatment efficacy are limited. In this study, we developed a statistical framework named Genomic Aberration-Derived Signature for Patient Stratification (GASPS) to characterize the transcriptomic deregulation of driver genomic aberrations and stratify patients. By applying GASPS to The Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) data, we developed gene signatures for 38 driver genomic aberrations, including gene mutations, amplifications, and deletions. These signatures were applied to independent lung cancer transcriptomic datasets containing a total of 2,226 patient samples. Our results indicated that these driver gene signatures are much more prognostic than their corresponding genomic mutations. Interestingly, the two EGFR-related signatures characterizing EGFR mutation and amplification, respectively, exhibited contrasting associations with prognosis, treatment response, and immune infiltration in the tumor microenvironment. Moreover, the STK11 mutation signature, rather than the mutation status, was found to be predictive of the response and long-term benefit of patients treated with immune checkpoint blockade therapy in lung cancer. This framework is readily applicable to most cancer types using existing data to improve prognostic risk assessment and treatment efficacy by guiding personalized therapies.
PMID:40909579 | PMC:PMC12407784 | DOI:10.1101/2025.08.21.671519
Extracting Clinical Guideline Information Using Two Large Language Models: Evaluation Study
Scalable generation and functional classification of genetic variants in inborn errors of immunity to accelerate clinical diagnosis and treatment
STAMP: Single-cell transcriptomics analysis and multimodal profiling through imaging
Spatial joint profiling of DNA methylome and transcriptome in tissues
Nature, Published online: 03 September 2025; doi:10.1038/s41586-025-09478-x
DNA-methylation and gene-expression profiling of tissue sections at near single-cell resolution can be used to create detailed spatial maps showing how methylation and transcription interact to shape cell identity and tissue development.Building the AI-enabled enterprise of the future
Artificial intelligence is fundamentally reshaping how the world operates. With its potential to automate repetitive tasks, analyze vast datasets, and augment human capabilities, the use of AI technologies is already driving changes across industries.

In health care and pharmaceuticals, machine learning and AI-powered tools are advancing disease diagnosis, reducing drug discovery timelines by as much as 50%, and heralding a new era of personalized medicine. In supply chain and logistics, AI models can help prevent or mitigate disruptions, allowing businesses to make informed decisions and enhance resilience amid geopolitical uncertainty. Across sectors, AI in research and development cycles may reduce time-to-market by 50% and lower costs in industries like automotive and aerospace by as much as 30%.
“This is one of those inflection points where I don’t think anybody really has a full view of the significance of the change this is going to have on not just companies but society as a whole,” says Patrick Milligan, chief information security officer at Ford, which is making AI an important part of its transformation efforts and expanding its use across company operations.
Given its game-changing potential—and the breakneck speed with which it is evolving—it is perhaps not surprising that companies are feeling the pressure to deploy AI as soon as possible: 98% say they feel an increased sense of urgency in the last year. And 85% believe they have less than 18 months to deploy an AI strategy or they will see negative business effects.
Companies that take a “wait and see” approach will fall behind, says Jeetu Patel, president and chief product officer at Cisco. “If you wait for too long, you risk becoming irrelevant,” he says. “I don’t worry about AI taking my job, but I definitely worry about another person that uses AI better than me or another company that uses AI better taking my job or making my company irrelevant.”

But despite the urgency, just 13% of companies globally say they are ready to leverage AI to its full potential. IT infrastructure is an increasing challenge as workloads grow ever larger. Two-thirds (68%) of organizations say their infrastructure is moderately ready at best to adopt and scale AI technologies.
Essential capabilities include adequate compute power to process complex AI models, optimized network performance across the organization and in data centers, and enhanced cybersecurity capabilities to detect and prevent sophisticated attacks. This must be combined with observability, which ensures the reliable and optimized performance of infrastructure, models, and the overall AI system by providing continuous monitoring and analysis of their behavior. Good quality, well-managed enterprise-wide data is also essential—after all, AI is only as good as the data it draws on. All of this must be supported by AI-focused company culture and talent development.
This content was produced by Insights, the custom content arm of MIT Technology Review. It was not written by MIT Technology Review’s editorial staff. It was researched, designed, and written entirely by human writers, editors, analysts, and illustrators. This includes the writing of surveys and collection of data for surveys. AI tools that may have been used were limited to secondary production processes that passed thorough human review.